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Background: Squamous cells are normally not found inside the breast. Therefore, a primary
squamous cell carcinoma of the breast is an exceptional phenomenon and the management
of  this type of disease is still debated.
Aim: Clinical outcome assessment of a patient with squamous cell carcinoma of the breast.
Materials and methods: We  report a case of primary squamous cell carcinoma of the breast
(T1cN0M0) in a 51-years-old woman who underwent breast conserving surgery plus adju-
vant chemotherapy and radiation therapy (RT).
Results: With a follow up of 43 months, the patient is alive with no evidence of local or distant
recurrence. The patient had Grade 2 acute skin toxicity. No late skin or respiratory toxicity
was  observed.
Conclusions: Pure primary squamous cell carcinoma of the breast is a rare and aggressive
disease, often treatment-refractory. Our case shows that the addition of RT after breastconserving surgery, allows to achieve a high local control without adding severe toxicity. A
multidisciplinary approach seems to be the optimal management for early stages in this
rare disease.
© 2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All.  Backgroundquamous cell carcinoma (SqCC) is a well-known malig-
ancy of the skin and other organs composed of squamous
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cells. SqCC of the breast is a very rare disease. The inci-
dence of primary SqCC of the breast is 0.04–0.1% of all breast, Clinica La Milagrosa, Calle Modesto Lafuente, 14, 28010 Madrid,
carcinomas.1–3 It is important to discriminate this entity from
malignancies of the skin of the breast or metastasis of a SqCC
somewhere else in the body. In the literature, only a few
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Fig. 1 – Breast ultrasound showing an irregular shaped
Pure primary squamous cell carcinoma of the breast is alesion containing liquid material.
small series are reported.1–3 Clinical and radiographic char-
acteristics are not speciﬁc, and tumors are usually hormone
receptor negative. In general, this tumor is very aggressive and
treatment-refractory with a poor prognosis. We  report a case
of this rare breast malignancy treated with breast conserving
surgery, adjuvant chemotherapy and radiation therapy (RT).
2. Aim
To assess the clinical outcome of a patient with squamous cell
carcinoma of the breast who  underwent postoperative RT.
3.  Methods  and  results
A 51-years-old, non-smoker woman with prior history of mas-
titis when she was 20 presented with a lump in the left
breast. A mammogram demonstrated an irregular abnormal-
ity in the left breast, which was classiﬁed as BI-RADS 4. Then,
the breast ultrasound revealed a hypoechoic lump measur-
ing 25 mm ×18 mm with a thick ring (Fig. 1). Fine needle
aspiration was performed with no evidence of malignancy
in the cytology. However, due to the high radiologic suspi-
cion of malignity, the patient underwent tumorectomy and
the pathology revealed a 20 mm × 19 mm well-differentiated
SqCC, originated from a focus of squamous metaplasia, close
to a papillary lesion and a ﬁbrocystic mastopathy area (Fig. 2).
Optimal surgical margins were obtained. Although a sentinel
lymph node biopsy4 is a standard for assessment of the sta-
tus of the axillary lymph nodes in patients with clinical stage
I–II breast cancer, the surgeon underwent a lymphadenectomy
due to the diagnosis uncertainty prior to the surgical proce-
dure. Seventeen axillary lymph nodes were dissected with
no evidence of disease. Hence, the tumor was classiﬁed as
stage IA (pT1pN0M0) according to the clinical TNM staging
system (American Joint Committee on Cancer Staging Man-
ual, 7th edition, 2002). Immunohistochemical evaluation was
negative for estrogen and progesteron receptors as well as foriotherapy 1 7 ( 2 0 1 2 ) 363–366
Her2/neu and Bcl2. It was positive for the epidermal growth
factor receptor (++), P54 (+++), and Mib1 (+++). In addition, the
Ki-67 proliferation index was found to be high. A magnetic res-
onance imaging of the left breast was performed after surgery
without any pathological enhancement. The diagnostic work
up to rule out other primary sites of SqCC included: whole
body scanning using computed tomography (CT), gynaecolog-
ical evaluation, and nose and throat examination.
The patient received adjuvant chemotherapy with four
cycles of 5-ﬂuorouracil, doxorubicin, and cyclophosphamide
plus another four cycles of Taxol. Then, the patient underwent
adjuvant RT with a three-dimensional conformal treatment
planning system. A CT simulation scan covering the entire
thoracic region from the apex of the lung to the diaphragm
was performed. Target and non-target volumes were outlined
according to the criteria of the International Commission of
Radiation Units and Measurements 62.5,6 The clinical tar-
get volume (CTV) was deﬁned as the entire palpable breast
tissue starting 5 mm below the skin. The planning target vol-
ume  (PTV) was obtained by adding a 10 mm margin to the
CTV, except in the skin. Radiation ﬁelds were appropriately
customized by a multileaf collimator when needed in order
to spare the surrounding healthy tissues. The angle of the
beams was adjusted to minimize the irradiation of the lung
parenchyma and left ventricle. Appropriate physical wedge
compensation was used to ensure a uniform dose distribu-
tion throughout the target volume. The total dose prescribed
to PTV was 50 Gy, delivered with 2 Gy daily for 5 days a week. A
boost dose of 10 Gy in 5 fractions was given using 6 MV  photon
beams, depending on the depth of the original tumor site. The
tumor bed was boosted mainly for two reasons: (1) the unfa-
vorable histology (squamous cell carcinoma) and (2) the young
age of the patient (51 y/o). The treatment technique consisted
primarily of four tangential ﬁelds using 6 MV photon beams
and then, for the boost, two ﬁelds at 0◦ and 90◦. The dose vol-
ume  histogram (DVH) for the lung and heart was calculated.
No more  than 9% of the lung received more  than 20 Gy, and
no more  than 1% of the heart received more  than 10 Gy. Dur-
ing the course of radiotherapy, the patient was seen weekly
for clinical evaluation and disease management. The patient
experienced acute Grade 2 skin toxicity, according the Radia-
tion Therapy Oncology Group (RTOG) scoring system. No late
skin or respiratory toxicity was observed.
The patient was evaluated at approximately 3 months
after completion of therapy and then 3–6 months afterwards.
Follow-up evaluations consisted of an interval history and
physical examination. Follow-up imaging typically involved
a mammography. Additionally, tumor markers including car-
cinoembryonic antigen, carbohydrate 15–3 and SqCC antigen
were assessed during the follow-up, always staying in the nor-
mal  range. With a follow-up of 43 months, the patient is alive
with no evidence of local or distant recurrence.
4.  Discussionrare condition and is considered to arise through metaplastic
change of ductal carcinoma cells.7 The concept of a disease
continuum with varying degrees of squamous metaplasia
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Fig. 2 – Histology appearance of squamous cell carcinoma well-differentiated on hematoxylin and eosin stain showing (A)
atypical keratinocytes and necrotic areas and (B) ductal dilatations, calciﬁcations, and chronic ﬂogosis.
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oas supported by Stevenson et al. who concluded that SqCC
ostly represents an extreme form of squamous metaplasia
ithin adenocarcinoma.7 An alternative theory is that it arises
irectly from the epithelium of the mammary  ducts. The SqCC
f the breast is generally large (>4 cm)  at diagnosis and cystic in
0% of cases.1 The prognosis of this type of breast cancer is still
egarded as somewhat controversial, although many  studies
uggest that it is an aggressive disease that may behave like a
oorly differentiated breast carcinoma.8–10
The breast SqCC is usually a high grade and hormone
eceptor-negative tumor.11 This means that hormone based
herapy may not be effective in these tumors. Her2/neu is also
sually not over-expressed or ampliﬁed in this desease.12 The
mmunohistology of our case is consistent with those ﬁndings.
he high frequency of EGFR positivity is interesting and may
e exploited in the development of future treatments.
In contrast with other studies,13 which showed that no
ndings on mammography are speciﬁc for this diagnosis,
hich may explain the advanced disease stage at the diagno-
is, our case had a mammogram demonstrating an irregular
bnormality in the left breast. This ﬁnding allowed to detect
n early stage. Breast ultrasound has been reported to be more
elpful with these tumors appearing as solid hypoechogenic
asses with complex cystic components.14
Because of its rarity, the most appropriate therapeutic reg-
men for SqCC of the breast is still unclear. A recent literature
eview reveals that an average of 70% of patients with SqCC
f the breast do not present axillary lymph nodes involve-
ent but due the unpredictable lymph nodes dissemination,
xillary lymph nodes dissection could always be performed
or staging purpose.7 As a result of the lack of data, the
ssue of whether to prescribe adjuvant treatment for SqCC
f the breast, remains unsolved.2 Some contribution can be
erived from the review by M.D.  Anderson group15 of clini-
al pathologic features, management and outcome of SqCC of
he breast in a series of 33 patients. Nineteen of the 31 patients
ith localized disease received adjuvant chemotherapy and 5
atients received neoadjuvant chemotherapy. The tumor did
ot respond to neoadjuvant chemotherapy in any patients. No
igniﬁcant difference was seen in relapse free survival or over-
ll survival rates between the patients treated with adjuvant
r neoadjuvant chemotherapy and those not treated.16 Theseﬁndings are consistent with Rostock et al. who  suggested that
SqCC is not sensitive to chemotherapeutic agents commonly
used for ductal carcinoma such as methotrexate, cyclophos-
phamide, 5-ﬂuorouracil (5-FU) and antracycline.12 In our case
report the patient received adjuvant chemotherapy with 5-
FU and cisplatin based on other experiences derived from
some reports.2,8,17,18 The role of radiation therapy has been
reported as unclear in many  studies. Although SqCC are gen-
erally radiosensitive, loco regional relapse occurred frequently
also in irradiated ﬁelds. It seems that SqCC of the breast
is often relatively radioresistant.2,7,17,18 However, considering
the conservative surgery performed, our case underwent RT
with no evidence of disease after 43 months of follow up.
5.  Conclusions
Pure primary squamous cell carcinoma of the breast is a rare
and aggressive disease often reported as treatment-refractory.
Rates of local failure after surgery for such patients have been
reported to be as high as 30%.15 Our case shows that the addi-
tion of RT after breast conservation surgery, allows to achieve
a high local control without adding severe toxicity. The dose of
radiation therapy used was similar to that typically employed
in the treatment of more  common inﬁltrating carcinomas.
The good control achieved argues against the idea that these
tumors are inherently radio resistant. Therefore, a multidis-
ciplinary approach seems to be the optimal management for
early stages of this rare disease. Future studies using novel
radiation approaches,19,20 such as partial breast irradiation,
are needed for this particular type of disease.
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